Practice Economics

EpiPen cost increases far exceed overall medical inflation


 

References

Total Medicare part D spending on EpiPen auto-injectors rose from $7.0 million in 2007 to $87.9 million in 2014 – an increase of 1,151%, according to an analysis released Sept. 20 by the Kaiser Family Foundation.

The number of EpiPen users also increased over that time, however, bringing with it a commensurate 159% rise in the number of prescriptions. Those two trends took the average cost of a single EpiPen prescription from $71 in 2007 to $344 in 2014, the Kaiser analysis showed.

That increase in cost per prescription did not fail to at least double overall medical care price inflation for each year from 2008 to 2014. In 2008, when the two trends were closest together, the EpiPen cost per prescription rose 7.4% from the year before, compared with 3.7% for overall medical spending. In 2014, Medicare part D’s cost for an EpiPen prescription rose 34% from the year before, which was 14 times higher than the 2.4% increase in total medical spending, Kaiser noted.

The analysis was based on a 5% sample of Medicare prescription drug event claims and included beneficiaries who had a least 1 month of part D coverage and one EpiPen prescription during the year. Estimates are not adjusted for inflation and do not include any possible manufacturer discounts, Kaiser said.

rfranki@frontlinemedcom.com

Recommended Reading

Vitamin D supplementation cuts dust mite atopy
MDedge Dermatology
Crisaborole’s safety holds up in long-term atopic dermatitis trial
MDedge Dermatology
Skin patch testing pinpoints dietary triggers of IBS
MDedge Dermatology
Nonwhite race, lower socioeconomic status predicts persistently active AD
MDedge Dermatology
Nonwhite race, lower socioeconomic status predicts persistently active AD
MDedge Dermatology
Study links severe childhood eczema to sedentary behaviors
MDedge Dermatology
Serum vitamin D levels, atopy not significantly linked
MDedge Dermatology
Food allergy testing only rarely needed for AD patients
MDedge Dermatology
Nonpharmacologic AD therapy: Strongest evidence supports moisturizers
MDedge Dermatology
Mylan’s generic EpiPen – a price break or marketing maneuver?
MDedge Dermatology